Standard Biotools (LAB) Liabilities from Discontinued Operations (2024 - 2025)
Standard Biotools (LAB) reported Liabilities from Discontinued Operations of 25633000.0 for Q4 2025, up 23.21% year-over-year from 20804000.0 in Q4 2024, and up 15.39% on a QoQ basis from 22214000.0 in Q3 2025.
Standard Biotools (LAB) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 25633000.0 in Q4 2025.
- Quarterly Liabilities from Discontinued Operations rose 23.21% year-over-year to 25633000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 25633000.0 (up 23.21% YoY) and the FY2025 annual result came in at 25633000.0, up 23.21% from the prior year.
- Liabilities from Discontinued Operations improved to 25633000.0 in Q4 2025 per LAB's latest filing, from 22214000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 25633000.0 in Q4 2025 and bottomed at 17984000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Standard Biotools | 448.37 Mn | -6.80 Mn | 11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.63 Mn |
| Dec 31, 2025 | 25.63 Mn |
| Sep 30, 2025 | 22.21 Mn |
| Sep 30, 2025 | 22.21 Mn |
| Jun 30, 2025 | 17.98 Mn |
| Jun 30, 2025 | 17.98 Mn |
| Dec 31, 2024 | 20.80 Mn |
| Dec 31, 2024 | 20.80 Mn |